IRIDEX posts a narrower year-over-year net loss per share in Q1'26 as strong glaucoma product sales and lower operating costs helped offset weakness in retina sales and supply-chain disruptions.
IRIDEX Corporation (IRIX) Q1 2026 Earnings Call Transcript
IRIX incurs narrower year-over-year loss per share in Q4 as growth in retina systems and glaucoma probes boosts revenues, though margins remain pressured by higher costs.
| Electrical Equipment Industry | Industrials Sector | Patrick Mercer CEO | NASDAQ (CM) Exchange | 462684101 CUSIP |
| US Country | 93 Employees | - Last Dividend | - Last Split | 15 Feb 1996 IPO Date |
IRIDEX Corporation is an ophthalmic medical technology company at the forefront of developing and providing innovative laser systems, delivery devices, and consumable instrumentation designed to treat sight-threatening eye diseases in the field of ophthalmology. With its roots going back to 1989 and originally known as IRIS Medical Instruments, Inc., the company underwent a name change to IRIDEX Corporation in November 1995. From its headquarters in Mountain View, California, IRIDEX has committed itself to serve ophthalmologists, research and teaching hospitals, government installations, surgical centers, veterinary practices, and office clinics both in the United States and internationally. Products are marketed directly as well as through a network of independent distributors worldwide, demonstrating their global reach and commitment to addressing eye health.
IRIDEX Corporation offers a wide range of high-quality ophthalmic laser systems and accessories designed for various treatments. Here are some of their key products and services:
IRIDEX's commitment to innovation is evident in their comprehensive range of products and services designed to meet the needs of ophthalmologists and their patients globally.